丹蒌片治疗痰瘀互结型冠心病的Meta分析

Danlou Tablet in the Treatment of Coronary Heart Disease with Phlegm and Stasis Mutual Obstruction Syndrome: A Meta Analysis

目的评价丹蒌片治疗痰瘀互结型冠心病的疗效及安全性。方法计算机检索Cochrane图书馆、PubMed数据库、中国生物医学文献数据库(CBMdisc)、中国期刊全文数据库(CNKI)、万方数据库、维普资讯网及中国临床试验注册中心正在进行的相关研究。两名研究员独立地按照预先设定的纳入标准与排除标准提取资料,应用Cochrane ROB tool进行方法学质量评价,并应用GRADE评分进行证据级别推荐,采用RevMan5.2软件进行统计分析。结果共收集丹蒌片治疗痰瘀互结型冠心病的文献101篇,最终进入Meta分析的研究共8项,纳入病人570例。Meta分析结果显示:在常规治疗的基础上给予丹蒌片治疗冠心病,可明显改善心绞痛疗效及心电图疗效,并降低心绞痛发作频率、减少心绞痛发作持续时间,此外,还可明显改善血脂水平、降低炎症因子水平,并无明显不良反应,安全有效。结论在常规治疗基础上加用丹蒌片治疗痰瘀互结型冠心病,可进一步改善冠心病的临床症状、心电图,减少心绞痛发作频率、时间,并改善血脂水平、降低炎症因子水平。

Objestive To assess the clinical efficacy and safety of Danlou tablet in the treatment of coronary heart disease（CHD） with phlegm and stasis mutual obstruction syndrome. Methods Relevant studies of Danlou tablet for treatment of CHD were collected from databases including Pubmed, Cochrane library, CNKI, VIP, Wanfang Database and CBMdisk.ln addition, we also searched data- bases of ongoing trials; Clinical Trials.gov.Two reviewers screened literature according to the inclusion and exclusion criteria,extrac- ted data and assessed the quality of the included studies independently.We used Cochrane ROB tool to assess the quality of meth- ods,we also recommend the level of evidence use GRADE score.Results We included 8 papers about Danlou tablet for CHD with phlegm and stasis mutual obstruction syndrome （8 papers and 507 participants）.The results of Meta analysis showed that the treatment group treated by Danlou tablet and western medicine could improve the efficacy of angina and electrocardiographic （ECG）, reduced the angina attack frequency and its cluration.lt could also improve the level of blood lipid and inflammatory factor.The results showed that Danlou tablet were safe and had no obvious side effects.Conclusion Danlou tablet can improve the clinical symptoms and ECG in CHD with phlegm and stasis mutual obstruction syndrome, it can also reduce the the angina attack frequency and its du- ration, improve the blood lipid and reduce the inflammatory factor.But the evidence is inadequate because of the potential biases exis- ted in those trials influencing the reliability of this conclusion.The evidence is inadequate and it needs more rigorous trials with high quality to give high level evidence to support the effectiveness of Danlou tablet for CHD.